Segall Bryant & Hamill, LLC Halozyme Therapeutics, Inc. Transaction History
Segall Bryant & Hamill, LLC
- $7.16 Billion
- Q3 2024
A detailed history of Segall Bryant & Hamill, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 355,176 shares of HALO stock, worth $17.2 Million. This represents 0.28% of its overall portfolio holdings.
Number of Shares
355,176
Previous 305,320
16.33%
Holding current value
$17.2 Million
Previous $16 Million
27.1%
% of portfolio
0.28%
Previous 0.29%
Shares
11 transactions
Others Institutions Holding HALO
# of Institutions
544Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$854 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$625 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$322 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$197 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$165 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.75B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...